leisure time -WSS

leisure time

author：focus 2025-08-12 09:08:39 - browse：13195

Adobe

LONDON — Merck said Wednesday it is buying ophthalmology-focused startup EyeBio in a deal worth up to $3 billion, as the pharma company looks to diversify its pipeline.

Under the deal, Merck, through a subsidiary, will pay $1.3 billion in cash upfront, with another $1.7 billion potentially included if certain regulatory and commercial milestones are met. The Wall Street Journal first reported the news Tuesday night.

EyeBio has been developing a drug called restoret for a number of retinal diseases, including age-related macular degeneration and diabetic macular edema. It presented data in February from a Phase 1/2 trial of restoret in both conditions. Merck said it plans to move restoret into a pivotal trial for diabetic macular edema later this year.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Wildfire smoke exposes gaps in outdoor worker protections
Next article： Nearly two

knowledge

WSS

ASCO: AstraZeneca says CAR

Trump drops motion seeking removal of DA probing efforts to overturn 2020 election in Georgia

See how much Covid

BMI, flaws aside, is found to be useful estimate of body fat in youth

At ASCO, pharma leaders speak of advances in 'smart bomb' drugs

Who is Magistrate Judge Moxila Upadhyaya in Trump's Jan. 6 case?

hotspot

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

focus

Tori Bowie and the unacceptable rates of Black maternal death

Ionis drug prevents swelling attacks due to hereditary angioedema

Hepatitis C has a cure — but many Americans still lack access to it

Verily hires former Apple Health leader as chief scientific officer

Supreme Court strikes down use of affirmative action

ProMED, early warning system on disease outbreaks, in peril

Sports medicine is finally prioritizing gender equality

ASCO Daily Recap: Safety data from Novartis, survival from Pfizer

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Stem cell clinics for heart failure: buyer be wary

knowledge

For one rare type of lung cancer, Pfizer pill reduces progression by 81%

Nearly two

For one rare type of lung cancer, Pfizer pill reduces progression by 81%

Woman returns to dialysis after doctors remove transplanted pig kidney

ASCO: AstraZeneca's hat trick, and palliative care's spotlight

Wild otter attack leads to woman being airlifted to hospital, 2 others treated for injuries

leisure time

hotspot

knowledge

leisure time